Background An increasing body of evidence supports an essential role for endoplasmic reticulum stress (ERS) in colorectal cancer (CRC). In this study, we developed an ERS‐related genes (ERSRGs) model to aid in the prognostic evaluation and treatment of CRC patients. Methods The training set and validation set data were extracted from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), respectively. ERSRGs were obtained from the GeneCards database. A prognostic risk scoring model was constructed using the least absolute shrinkage and selection operator (LASSO) along with univariate Cox regression analysis. To further predict the probability of survival for patients at 1, 2, and 3 years, a nomogram was devised. The advantages of the prognostic risk score model in screening patients’ sensitive to chemotherapy and immunotherapy were analyzed by drug sensitivity analysis and immune correlation analysis. Finally, hub genes associated with poor prognosis in the risk model were screened by Protein–protein interaction (PPI) network and their expression was validated using clinical specimens. Results A risk model for overall survival (OS) was developed using 16 ERSRGs associated with prognosis. Through analyses, we demonstrated a high degree of reliability for the prognostic risk scoring model. The constructed nomograms performed well in predicting patient survival over 1, 3, and 5 years. The calibration curve and decision curve analysis (DCA) supported a high degree of accuracy for the model. Patients in the low‐risk group had a lower IC50 for the common chemotherapy drug, 5‐FU, and responded better to immunotherapy. hub poor prognostic genes were validated in CRC clinical specimens. Conclusion We have identified and validated a new ERS prognostic marker that can accurately predict the survival status of CRC patients for clinicians and better provide personalized treatment plans.
Background.Coronin 2A (CORO2A) is a member of the coronin family and reportedly functions as an oncogene in certain malignancies, although its correlation with prognosis and immune infiltration in different cancers remains unclear. Methods.Data were collected from the University of California Santa Cruz (UCSC), Human Protein Atlas (HPA), Tumor Immune Estimation Resource (TIMER), Tumor-Immune System Interactions (TISIDB) and Gene Set Enrichment Analysis (GSEA) databases. The differential expression of CORO2A, survival, clinical parameters, tumor mutational burden (TMB), microsatellite instability (MSI), mismatch repair (MMR) genes, DNA methyltransferases (DNMTs), tumor microenvironment (TME), immune-related genes (IRGs), immune infiltration, pathways and functions were analyzed using the R language software. Results.CORO2A was overexpressed in various malignancies, and correlated with clinical parameters, overall survival, disease-specific survival and progression-free survival in certain cancers. Furthermore, CORO2A was significantly correlated to the TMB, MSI, MMR genes, DNMTs, immune and stromal scores, IRGs and immune infiltration. GSEA further showed that CORO2A was associated with various immune-related pathways and functions in different cancer types. Conclusion.CORO2A is a promising prognostic and immunological marker for human cancers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.